Acasti Announces Court Dismissal of Stockholder Litigation
September 30, 2022 09:00 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
September 29, 2022 09:00 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...
Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference
September 14, 2022 16:15 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
September 13, 2022 08:00 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic...
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 09:00 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery...
Acasti Pharma Reports First Quarter 2023 Operational Results
August 11, 2022 07:00 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery...
Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022
August 02, 2022 16:15 ET
|
Acasti Pharma, Inc.
Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST),...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
July 27, 2022 08:00 ET
|
Acasti Pharma, Inc.
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK)...
Acasti Pharma Announces Annual Grants of Performance Stock Options
June 22, 2022 18:10 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery...
Acasti Pharma Reports Fiscal Year 2022 Operational Results
June 21, 2022 08:00 ET
|
Acasti Pharma, Inc.
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, June 21, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,...